COVID-19: Kaneka supplies PCR reagents: Kaneka Eurogentec / First 200,000 bottles
COVID-19: Kaneka
In Belgium and neighboring countries, Kaneka Eurogentec, a Kaneka group company, will boost production of PCR reagents.
At the request of the Belgian government, PCR test reagents are used for new coronavirus tests.
Started supplying 200,000 equivalents / PCR test reagents for the first time to hospitals / laboratory / research institutions in Belgium / neighboring countries.
Belgium: Namur University
Succeeded in developing a simple detection method (does not use special equipment-specific reagents).
Approved by the Belgian Federal Medical and Health Products Agency as a new coronavirus test method.
For this test, PCR test reagent (Takyon) of Kaneka Eurogentec was adopted.
This is a request from the Belgian authorities for supply.
Kaneka Eurogentec:
It is expected to be applied to vaccines and therapeutics.
We have world-class technology for high quality messenger RNA (mRNA) and plasmid DNA.
Food Industry News WEB
https://www.ssnp.co.jp/news/soy/2020/04/2020-0408-1350-16.html
Kaneka Eurogentec begins supplying reagents for novel coronavirus testing Kaneka Corporation
April 2, 2020
Kaneka Eurogentec S.A. (Headquarters: Liège, Belgium; President: Lieven Janssens), an affiliate of Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka),
has reinforced production of PCR*1 reagents used in the novel coronavirus testing, as per requested by the Belgian government.
They have begun supplying hospitals, testing organizations and research institutes in Belgium and its neighboring countries with enough PCR reagents to conduct around 200,000 tests for the first shipment.
University of Namur (Namur, Belgium)
has succeeded in developing a convenient detection method that refrains from using reagents that require specialized equipment,
this was approved as a method for the novel coronavirus testing by Belgium’s Federal Agency for Medicines and Health Products.
The method
uses Kaneka Eurogentec’s PCR reagent (TakyonTM), which led to the request from the Belgian authorities to supply the reagent.
Kaneka Eurogentec S.A.
also possesses world-leading technologies for high quality mRNA*2 and plasmid DNA*3.
They have strengthened GMP*4 manufacturing of mRNA and plasmid DNA in order to respond to growing inquiries on a novel coronavirus vaccine, which pharmaceutical companies and biotech ventures are accelerating development of.
Kaneka will put in every effort to provide solutions to the novel coronavirus for worldwide health.